- BiocSol raises €4.4 million, bringing it closer to its €10 million target for advancing sustainable crop protection through biofungicides.
- Funding from Pymwymic and the Walloon Region will accelerate R&D and support global proof-of-concept demonstrations.
- BiocSol’s innovations aim to replace chemical pesticides, offering environmentally friendly solutions to enhance food security and sustainable farming.
BiocSol, a spin-off from UCLouvain focused on sustainable crop protection, has raised an additional €4.4 million ($4.58 million) in funding, moving closer to its €10 million target.
The latest investment round includes contributions from Dutch impact investment firm Pymwymic and non-dilutive financing from the Walloon Region through the Win4company programme.
These funds will accelerate research and development and support global proof-of-concept demonstrations for BiocSol’s biofungicide products.
This follows a €5.2 million ($5.4 million) investment secured in November 2024, led by Agri Investment Fund and VIVES Partners, reflecting strong investor confidence in BiocSol’s mission to offer environmentally friendly alternatives to chemical pesticides.
CEO Denis Payen emphasized that reaching the €10 million milestone will enable the company to fast-track development and expand its sustainable solutions. He also welcomed Pymwymic’s involvement, citing its strategic value in scaling impact-driven initiatives.
BiocSol credits its progress to the support of the Walloon Region and research contributions from UCLouvain’s Laboratory of Plant Pathology and the Laboratory of Food and Environmental Microbiology.
Download the Ebook now
Pieter Vis, a partner at Pymwymic, praised BiocSol’s innovation, stating that its biosolutions could provide cost-effective alternatives for farmers while reducing environmental impact.
This funding positions BiocSol as a key player in the agricultural biotechnology sector, addressing global food security challenges with sustainable solutions that maintain crop yields and promote environmental health.